Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M612Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M12.5EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)27.3Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book2.910-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.9PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M4,000,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IHE

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

IHE is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


IHE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Keogh, WillemSenior Officer 2016-09-08Buy338$21.28619.17view
Sardo, Vincent JamesDirector 2016-09-08Sell1,500$43.05255.49view
Larson, Douglas RobertDirector, Senior Officer 2016-09-08Sell800$8.351732.81view
Fraser, AlisonDirector or Senior Officer of Insider or Subsidiar 2016-09-08Sell12,700$10.181403.34view
Brown, ArthurDirector 2016-09-08Sell250,000$0.07218528.57view
Brewster, NormanSenior Officer 2016-09-08Sell45,000$0.03510033.33view
Darling, Neil B.T.Director 2016-09-08Buy53,500$0.2756581.48view
Porter, Brian JDirector, Senior Officer 2016-09-08Sell25,176$70.17118.1view
Marsh, John M.Director 2016-09-08Sell36,000$29.5418.78view
Graham, Eric JohnSenior Officer 2016-09-08Buy1,700$3.234638.08view

Quarterly/Annual Reports about IHE:

    News about IHE:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals... Sep 12 2016
    Will a Clinton Presidency Spell Doom for Pharma ETFs? Sep 09 2016
    Why Pfizer’s Vaccines Business Is Declining Sep 01 2016
    Will Xtandi Fuel Pfizer’s Top-Line Growth? Aug 31 2016
    Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns Aug 31 2016
    Analyzing Johnson & Johnson’s Business Segments Aug 30 2016
    Pfizer’s Products with Decreasing Revenues Aug 11 2016
    Pharma ETFs Soaring on Solid Q2 Earnings Aug 03 2016
    Trending on ETFdb.com: Emerging Markets and Dividend Kings Garner Interest Jun 02 2016
    Government Study: Cellphone Radiation Linked To Cancer May 27 2016
    Mudslinging Over Valeant Pharmaceuticals May 07 2016
    Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus May 04 2016
    Finding Pharmaceuticals ETFs With Rebound Potential May 04 2016
    The Last Week of April Wasn’t Good for Biotechnology Stocks May 02 2016
    Fertilizer Impact: Natural Gas Prices Rise Yet Again for Week Ending April 22 Apr 28 2016
    A Segment-by-Segment Breakdown of JNJ’s 1Q16 Earnings Apr 25 2016
    5 Best Performing Bull Run Equity ETFs Mar 09 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)